Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a new drug combination consisting of two drugs,
vemurafenib (also known as ZelborafTM) and panitumumab (also known as VectibixTM). This
treatment is being tested in a subgroup of patients with colorectal cancer whose tumors have
changes in the BRAF gene that may make them more likely to respond to this new drug
combination.